Evidence for the IL-2-AhR-5HTP-dependent activation of T cell exhaustion is supported by human and laboratory animal studies, and this pro-oncogenic role for the AhR and 5HTP suggests that targeting the AhR to inhibit IL-2-dependent initiation of CD8 + T cell exhaustion may be feasible for treating breast cancer. The gene discussed is IL2; the disease is breast cancer.